Kura Oncology Inc. (NASDAQ:KURA) shares rose 9.4% on Wednesday . The stock traded as high as $4.13 and last traded at $3.61, with a volume of 412,583 shares changing hands. The stock had previously closed at $3.30.

KURA has been the subject of several research reports. Zacks Investment Research raised shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $3.75 price objective for the company in a report on Wednesday. Citigroup Inc. decreased their price objective on shares of Kura Oncology from $19.00 to $12.00 and set a “buy” rating for the company in a report on Monday, March 21st. Finally, Oppenheimer Holdings Inc. reissued an “outperform” rating and set a $16.00 price objective on shares of Kura Oncology in a report on Tuesday, June 21st.

The company’s 50 day moving average price is $2.98 and its 200 day moving average price is $3.96. The firm’s market capitalization is $96.99 million.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Wednesday, May 11th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.01. Equities analysts predict that Kura Oncology Inc. will post ($1.70) EPS for the current year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.